J F Paolini

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. doi request reprint Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
    John F Paolini
    Merck Research Laboratories, Rahway, NJ, USA
    Am J Cardiol 101:625-30. 2008
  2. ncbi request reprint Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors
    John F Paolini
    Merck and Company, Incorporated, 126 East Lincoln Avenue, Rahway, NJ 07065, USA
    Cardiol Clin 26:547-60. 2008
  3. pmc Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial
    J F Paolini
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Int J Clin Pract 62:896-904. 2008
  4. doi request reprint Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
    D Maccubbin
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Int J Clin Pract 62:1959-70. 2008
  5. doi request reprint Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia
    S Shah
    Merck Research Laboratories, Cardiovascular Disease, Merck, Sharp and Dohme Corp, Rahway, NJ 07065, USA
    Int J Clin Pract 64:727-38. 2010
  6. ncbi request reprint A comparison of the pharmacokinetics of two different formulations of extended-release niacin
    B Lauring
    Merck and Co, Inc, Rahway, NJ 07065 0900, USA
    Curr Med Res Opin 25:15-22. 2009
  7. ncbi request reprint Validation of a questionnaire to assess niacin-induced cutaneous flushing
    Josephine M Norquist
    Merck Research Laboratories, Department of Epidemiology, North Wales, PA 19454 2505, USA
    Curr Med Res Opin 23:1549-60. 2007
  8. doi request reprint Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease
    Darbie Maccubbin
    Merck Research Laboratories, Rahway, NJ, USA
    Am J Cardiol 104:74-81. 2009
  9. doi request reprint Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients
    Debra Kush
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Cardiology 114:192-8. 2009
  10. ncbi request reprint Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects
    E M Migoya
    Merck Research Laboratories, Rahway, NJ 07065 0900, USA
    Int J Clin Pharmacol Ther 44:83-92. 2006

Collaborators

Detail Information

Publications12

  1. doi request reprint Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
    John F Paolini
    Merck Research Laboratories, Rahway, NJ, USA
    Am J Cardiol 101:625-30. 2008
    ..LRPT plus ERN was well tolerated. In conclusion, the significant reduction in ERN-induced flushing provided by LRPT plus ERN supports an accelerated ERN dose-advancement paradigm to achieve rapidly a 2-g dose in dyslipidemic patients...
  2. ncbi request reprint Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors
    John F Paolini
    Merck and Company, Incorporated, 126 East Lincoln Avenue, Rahway, NJ 07065, USA
    Cardiol Clin 26:547-60. 2008
    ..ER niacin/laropiprant generally is tolerated well and represents a new treatment option for dyslipidemia that offers the potential for more patients to receive the lipid-modifying and cardiovascular benefits of niacin...
  3. pmc Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial
    J F Paolini
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Int J Clin Pract 62:896-904. 2008
    ..We developed the Flushing Symptom Questionnaire((c)) (FSQ), a quantitative tool to assess patient-reported flushing, and assessed its ability to characterise ER niacin-induced flushing...
  4. doi request reprint Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
    D Maccubbin
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Int J Clin Pract 62:1959-70. 2008
    ..Laropiprant (LRPT), a PGD(2) receptor (DP1) antagonist that reduces niacin-induced flushing has been combined with extended-release niacin (ERN) into a fixed-dose tablet...
  5. doi request reprint Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia
    S Shah
    Merck Research Laboratories, Cardiovascular Disease, Merck, Sharp and Dohme Corp, Rahway, NJ 07065, USA
    Int J Clin Pract 64:727-38. 2010
    ....
  6. ncbi request reprint A comparison of the pharmacokinetics of two different formulations of extended-release niacin
    B Lauring
    Merck and Co, Inc, Rahway, NJ 07065 0900, USA
    Curr Med Res Opin 25:15-22. 2009
    ..The objective of this study was to compare pharmacokinetic parameters of niacin extended-release tablets (NER uncoated) and niacin extended-release caplet formation (NER coated)...
  7. ncbi request reprint Validation of a questionnaire to assess niacin-induced cutaneous flushing
    Josephine M Norquist
    Merck Research Laboratories, Department of Epidemiology, North Wales, PA 19454 2505, USA
    Curr Med Res Opin 23:1549-60. 2007
    ..To further characterize flushing, a patient-reported Flushing Symptom Questionnaire (FSQ) was developed and validated...
  8. doi request reprint Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease
    Darbie Maccubbin
    Merck Research Laboratories, Rahway, NJ, USA
    Am J Cardiol 104:74-81. 2009
    ..In conclusion, improvement in flushing with ERN/LRPT versus gradually titrated N-ER supports a rapidly advanced 1-g --> 2-g dosing regimen, allowing patients to start at 1 g and quickly reach and tolerate the optimal 2 g dose of ERN...
  9. doi request reprint Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients
    Debra Kush
    Merck Research Laboratories, Rahway, NJ 07065, USA
    Cardiology 114:192-8. 2009
    ..This study compared flushing with a combination tablet of extended-release (ER) niacin (ERN)/LRPT to niacin ER (N-ER; without LRPT) during the first week of therapy among patients in Asia...
  10. ncbi request reprint Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects
    E M Migoya
    Merck Research Laboratories, Rahway, NJ 07065 0900, USA
    Int J Clin Pharmacol Ther 44:83-92. 2006
    ..To assess the bioequivalence of an ezetimibe/simvastatin (EZE/SIMVA) combination tablet compared to the coadministration of ezetimibe and simvastatin as separate tablets (EZE + SIMVA)...
  11. ncbi request reprint Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans
    Arthur J Bergman
    Merck Research Laboratories, WP75 100, Sumneytown Pike, West Point, PA 19486, USA
    J Clin Pharmacol 44:1054-62. 2004
    ..70, 1.43), no clinically significant pharmacokinetic drug interaction between fenofibrate and simvastatin was concluded in humans. The coadministration of simvastatin and fenofibrate in this study was well tolerated...
  12. ncbi request reprint Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects
    Arthur J Bergman
    Merck Research Laboratories, West Point, PA 19486, USA
    J Clin Pharmacol 46:321-7. 2006
    ..CyA concentrations should be monitored in patients receiving EZE and CyA...